And I'd consider that increase in valuation somewhat low if the drug is capable of doing what it's supposed to. $1 billion? If AGN licenses the drug for stroke in the American market, I'd be confident they could attain $2 billion+ valuation with significant royalties. I'm thinking at least 20-25% such is the potential upside. If she's talking about the value increasing 10 fold due to the inflection point reached post Phase 2 top line data results, that's probably more on the money.
Encouraging to hear Liz thinks they are still on track for an 18 month duration for the trial.
- Forums
- ASX - By Stock
- AGN Media thread
And I'd consider that increase in valuation somewhat low if...
-
- There are more pages in this discussion • 92 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AGN (ASX) to my watchlist
|
|||||
Last
79.0¢ |
Change
0.010(1.28%) |
Mkt cap ! $100.4M |
Open | High | Low | Value | Volume |
78.0¢ | 80.5¢ | 78.0¢ | $71.40K | 90.43K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 15000 | 78.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
80.5¢ | 2444 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 15000 | 0.785 |
1 | 10000 | 0.780 |
2 | 25477 | 0.775 |
2 | 16000 | 0.770 |
2 | 58000 | 0.760 |
Price($) | Vol. | No. |
---|---|---|
0.805 | 2444 | 1 |
0.830 | 2298 | 2 |
0.850 | 10650 | 2 |
0.860 | 12500 | 1 |
0.865 | 14194 | 2 |
Last trade - 15.55pm 23/08/2024 (20 minute delay) ? |
AGN (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online